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SPINK5, encoding the putative multi-domain serine protease inhibitor LEKTI, was recently identiﬁed as the
defective gene in the severe autosomal recessive ichthyosiform skin condition, Netherton syndrome (NS).
Using monoclonal and polyclonal antibodies, we show that LEKTI is a marker of epithelial differentiation,
strongly expressed in the granular and uppermost spinous layers of the epidermis, and in differentiated
layers of stratiﬁed epithelia. LEKTI expression was also demonstrated in normal differentiated human
primary keratinocytes (HK) through detection of a 145 kDa full-length protein and a shorter isoform of
125 kDa. Both proteins are N-glycosylated and rapidly processed in a post-endoplasmic reticulum
compartment into at least three C-terminal fragments of 42, 65 and 68 kDa, also identiﬁed in conditioned
media. Processing of the 145 and 125 kDa precursors was prevented in HK by treatment with a furin inhibitor.
In addition, in vitro cleavage of the recombinant 145 kDa precursor by furin generated C-terminal fragments of
65 and 68 kDa, further supporting the involvement of furin in LEKTI processing. In contrast, LEKTI precursors
and proteolytic fragments were not detected in differentiated HK from NS patients. Defective expression of
LEKTI in skin sections was a constant feature in NS patients, whilst an extended reactivity pattern was
observed in samples from other keratinizing disorders, demonstrating that loss of LEKTI expression in the
epidermis is a diagnostic feature of NS. The identiﬁcation of novel processed forms of LEKTI provides the
basis for future functional and structural studies of fragments with physiological relevance.
INTRODUCTION
Netherton syndrome (NS; MIM 256500) is a severe autosomal
recessive skin disorder characterized by ichthyosiform erythro-
derma, a specific bamboo hair defect (trichorrhexis invaginata)
and atopy. NS infants typically present at birth or soon after
with generalized exfoliative erythroderma, which persists
throughout life in the most severe cases or gradually evolves
into a milder condition known as ichthyosis linearis circumflexa
(1–3). Trichorrhexis invaginata is detectable by light micro-
scopy on a variable proportion of scalp and eyebrow hairs, and
corresponds to the atrophy and invagination of their distal parts
(2,4). Patients display a broad range of allergic manifestations
including atopic dermatitis, and markedly elevated serum
IgE levels (5,6). Most patients also experience recurrent, if
not persistent, bacterial infections (7). Histological and
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ultrastructural studies reveal an incomplete keratinization of the
epidermis and severely impaired cornification. The granular
layer is greatly reduced and may be lacking completely. The
highly variable clinical presentation, together with the
commonly delayed appearance of the pathognomonic bamboo
hair after infancy, makes NS difficult to diagnose in early life.
In the absence of specific treatment, NS prognosis is poor. The
neonatal period is often associated with a profound failure
to thrive, which leads to a fatal course in up to 20% of the
cases (8).
We recently identified SPINK5 (serine protease inhibitor
Kazal-type 5) as the defective gene in NS (9,10). A total of 34
SPINK5 mutations have been reported in patients, all of which
create premature termination codons of translation (10–13).
Northern blot analyses revealed a dramatic reduction of the
3.7 kb SPINK5 transcript levels in cultured human primary
keratinocytes (HK) from the majority of patients examined
(10,12), suggesting defective protein expression. SPINK5
encodes LEKTI (lympho-epithelial Kazal-type related inhibi-
tor), a predicted serine protease inhibitor. The protein consists
of 1064 amino acids organized into 15 potential inhibitory
Kazal-type domains (D1–D15), preceded by a signal peptide.
Only D2 and D15 perfectly match the typical Kazal motif
[C-(X)n-C-(X)7-C-(X)10-C-(X)2/3-C-(X)m-C], whilst other
domains exhibit a Kazal-type-derived four-cysteine residue
pattern. The isolation of individual domains D1, D5 and D6
from human hemofiltrate (14,15) revealed that LEKTI full-
length protein most likely represents an inactive precursor, the
proteolytic processing of which would be required for the
release of bioactive forms. A 30 kDa polypeptide with an N-
terminal sequence matching D8 of LEKTI was also purified
from HK conditioned medium (16).
Subtilisin-like proprotein convertases (SPC) are a family of
endoproteases responsible for the processing of numerous
inactive prohormones and other proproteins into their biologi-
cally active forms (17). SPCs display a specific tissue
distribution and cellular localization (17), and cleave their
substrates at the general motif (K/R)-Xn-(K/R);(n¼ 0, 2, 4 or
6; X-any amino acid) (18). A number of these consensus
sequences have been identified within the amino-acid sequence
of LEKTI, suggesting that SPCs may be involved in the
proteolytic processing of LEKTI (13).
Analysis of the human tissue distribution of SPINK5
transcripts predicts high expression levels of LEKTI in thymus,
vaginal epithelium, oral mucosa, tonsils and Bartholin’s and
parathyroid glands (14). More recently, in situ hybridization has
revealed the localization of SPINK5 transcripts to the upper-
most spinous layers and the granular layer of normal human
epidermis (13). The authors also reported a marked increase in
trypsin-like hydrolytic activity in the cornified layer of NS
patients. This finding, together with the demonstration of a
trypsin-inhibiting activity for D5 and D6 domains (14,15),
supports a key role for LEKTI in the regulation of proteolytic
events involved in skin barrier formation and maintenance.
To further characterize LEKTI human tissue distribution and
investigate protein expression in HK from normal controls and
NS patients, we developed monoclonal and polyclonal anti-N,
and polyclonal anti-C terminal, antibodies. We report the first
detection of the full-length protein, together with the
identification of a shorter isoform in normal HK. We show
that both precursors are N-glycosylated and rapidly cleaved in a
post-endoplasmic reticulum compartment to generate at least
three C-terminal fragments, and provide evidence that furin is
involved in LEKTI processing. We also describe the protein
expression in normal stratified epithelia, and demonstrate that
loss of LEKTI expression in the epidermis is a diagnostic
feature of NS.
RESULTS
Characterization of LEKTI expression in normal HK
Given the predicted expression of LEKTI in the uppermost
differentiated layers of the epidermis, we assessed the
immunospecificity of the newly generated antibodies on
proliferating and differentiated cultured HK. Terminal differ-
entiation was induced by switching the ionic calcium content of
the culture medium from low (<0.1mM) to high (1.2mM)
concentrations, as previously described (19,20).
Immunolocalization of LEKTI. HK were cultured for 24 h in
low or high calcium conditions and analysed by immunofluor-
escence microscopy using antibodies generated against the C-
terminus of LEKTI (a-C). A strong labelling was observed in
differentiated cells (Fig. 1B; green) whilst only very low pro-
tein levels were present in cells grown in proliferating condi-
tions (Fig. 1A). No labelling was observed using pre-immune
serum (data not shown). The specificity of labelling was subse-
quently confirmed by antigen competition experiment.
Incubation of antibodies with recombinant antigen, prior
to immunodetection, led to a dramatic reduction in signal
Figure 1. Immunolocalization of LEKTI in HK. HK were cultured in prolifer-
ating (low-calcium medium; A) or differentiating (high-calcium medium; B–F)
conditions for 24 h, and processed for immunofluorescence microscopy analy-
sis as described in Materials and Methods. (A–C) Cells were immunostained
with LEKTI polyclonal a-C antibodies (green) pre-incubated in the presence
(þ) or absence () of the recombinant antigen GST-D13-D15 prior to immu-
nodetection. Cells were counterstained with propidium iodide to reveal nuclei
(red). (D–F) Cells were double stained with a-C (D) and anti-calreticulin (E)
antibodies. The degree of overlap between the two proteins is represented by
the yellow signal in the merged image (F). The results shown are representative
of three to five independent experiments.
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intensity (Fig. 1C). Since the labelling showed an extensive reti-
cular pattern characteristic of the endoplasmic reticulum (ER),
we performed double staining using a-C antibodies (Fig. 1D)
and an antibody specific for the ER marker protein, calreticulin
(Fig. 1E). Superimposition showed significant overlap (Fig. 1F),
indicating that the majority of LEKTI is localized in the ER.
Similar results were obtained using antibodies generated against
the N-terminus of LEKTI (a-N; data not shown).
Molecular detection of LEKTI. HK were cultured as above,
and analysed by western blot using a-C antibodies (Fig. 2A).
Three bands of 42, 65 and 68 kDa were detected in total
cell extract (lane 2) and conditioned medium (lane 3) from
differentiated cells, but not in undifferentiated cells (lane 1).
These signals were not detected using pre-immune serum
(Fig. 2B; lane 1) or a-N antibodies (data not shown). As above,
we confirmed the signal specificity by antigen competition
experiment (Fig. 2B; lanes 2 and 3). We also examined a
lower protein molecular weight range, but no additional N-
or C-terminal-specific fragments were identified by the corres-
ponding antibodies (data not shown).
The molecular weight of LEKTI predicted by the amino acid
sequence is 118 kDa. Although both a-N and a-C antibodies
detected LEKTI in the ER of differentiated HK, only 42, 65
and 68 kDa proteins were identified in the corresponding cell
Figure 2. Molecular detection of LEKTI in HK. HK were cultured in proliferating (low-calcium medium) or differentiating (high-calcium medium) conditions for
24 h. Twenty microgram protein samples were separated by SDS–PAGE (7.5%) and analysed by western blot. (A) Total cell extracts (lanes 1 and 2) and conditioned
medium (lane 3) from proliferating (lane 1) and differentiated (lanes 2 and 3) cells were analysed using LEKTI polyclonal a-C antibodies. Anti-tubulin detection
shows equal loading of cell extracts. (B) Total cell extracts from differentiated cells were analysed using a-C antibodies (lanes 2 and 3) pre-incubated in the pre-
sence (þ) or absence () of the recombinant antigen, or using the pre-immune serum (lane 1). (C) Total cell extracts from differentiated cells cultured for an
additional 6 h in the presence (þ) or absence () of BFA at 10mg/ml were analysed using LEKTI polyclonal a-C (lanes 1 and 2) and a-N (lanes 3 and 4) antibodies.
(D) Total cell extracts from differentiated cells treated with BFAwere analysed using LEKTI polyclonal a-C (lanes 2 and 3) and a-N (lanes 5 and 6) antibodies pre-
incubated in the presence (þ) or absence () of the respective recombinant antigens (GST-D13–D15 and GST-D1–D6), or using the corresponding pre-immune
sera (lanes 1 and 4, respectively). The asterisk indicates an unrelated protein cross-reacting with a-N antibodies, which is also present in samples from NS patients
(data not shown). Arrows indicate the positions of the 42, 65, 68, 125 and 145 kDa protein bands. Molecular weight markers are indicated on the left in kDa. The
results shown are representative of three to five independent experiments.
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extracts by a-C antibodies. These data suggest that LEKTI is
rapidly processed in a post-ER compartment and that the 42, 65
and 68 kDa proteins represent C-terminal proteolytic forms. In
an attempt to detect the full-length protein, we treated
differentiated HK with brefeldin A (BFA), a drug that blocks
ER to Golgi protein transport (21). Western blot analysis of
these cell extracts (Fig. 2C) revealed two high molecular
weight bands of 125 and 145 kDa using a-C (lane 2) and a-N
(lane 4) polyclonal antibodies, that were not detected in
the absence of BFA (lanes 1 and 3, respectively). Note that
only very low levels of the three C-terminal fragments were
detected under such conditions (lane 2). In contrast, pre-
immune sera failed to recognize the 125 or 145 kDa proteins
(Fig. 2D; lane 1, a-C and lane 4, a-N). The specificity of these
bands was further confirmed by antigen competition experi-
ments (Fig. 2D; lanes 2 and 3, a-C and lanes 5 and 6, a-N),
indicating that both the 125 and 145 kDa proteins were derived
from LEKTI.
LEKTI is expressed as two N-glycosylated
precursor isoforms in HK
We previously detected the expression of a single 3.7 kb
SPINK5 transcript in cultured HK (10,12), whose size is
consistent with the full-length protein (14). Since BFA
treatment revealed two specific signals, we tested whether the
145 kDa band could correspond to the glycosylated form of
the 125 kDa protein, which approximately matches LEKTI
predicted size. Total cell extracts from differentiated HK treated
with BFA were incubated in the presence or absence of the
peptide N-glycosidase F (PGNaseF) and analysed by western
blot using a-C antibodies. PGNase F treatment resulted in a
molecular weight shift of 10 kDa for both proteins (Fig. 3;
compare lanes 1 and 2). These results indicate that the 125 and
145 kDa bands correspond to N-glycosylated forms of two
separate precursors of LEKTI, with apparent molecular
weights of 115 and 135 kDa, respectively.
To confirm the identity of the 145 kDa band as the N-
glycosylated form of LEKTI full-length precursor, COS-1 cells
were transfected with full-length LEKTI cDNA. Western blot
analysis using a-N (data not shown) or a-C (Fig. 3) antibodies
showed expression of a 145 kDa band in total protein extract
from LEKTI cDNA transfected cells (lane 4), but not from
mock transfected cells (lane 3). A 135 kDa protein was detected
after PGNaseF treatment (lane 5), consistent with the result
obtained in HK (lane 2).
Furin is involved in the processing of LEKTI in HK
The absence of cleavage of the recombinant full-length protein
in COS-1 cells prompted us to test furin, a subtilisin-like
proprotein convertase expressed in the epidermis (22), as a
potential candidate for the endoproteolytic processing of
LEKTI.
Protein extracts from COS-1 cells overexpressing LEKTI
were incubated with human recombinant furin for increasing
times, and analysed by western blot using a-C antibodies
(Fig. 4A). Interestingly, the appearance of 65 and 68 kDa
fragments were first detected 7min after furin addition
(lane 3), and were not observed in total cell extracts (lane
1), or after a short 3min incubation (lane 2), a time when the
145 kDa full-length protein was evident. Importantly, an
increase in intensity of the 65 and 68 kDa proteolytic
fragments was observed with increasing incubation times,
and was mirrored by a loss in signal of the full-length protein
(compare lanes 2–6). Processing reached a maximum at
60min, when very little precursor protein was detected (lane
6). In contrast, mock-treated cells showed no processing of
LEKTI after 60min (lane 7). The 65 and 68 kDa proteolytic
products generated from incubation of over-expressed LEKTI
with furin in these experiments migrated at the same size as
two of the C-terminal proteolytic forms identified in HK
(Fig. 2).
To confirm the involvement of furin in the physiological
processing of LEKTI, differentiated HK were cultured for 6 h
with increasing concentrations of the furin inhibitor, Dec-
RVKR-CMK, or in the presence of brefeldin A (BFA) as a
control (Fig. 4B). Consistent with our previous results
(Fig. 2), incubation with BFA led to the detection of the
125 and 145 kDa proteins, with the concomitant loss of 42,
65 and 68 kDa proteolytic fragments (lane 4), whilst the
precursors were not observed in untreated cells (lane 1).
Significantly, incubation with the furin inhibitor (lanes 2
and 3) had a similar effect to that of BFA: there was a strong
inhibition of processing of the native 125 and 145 kDa
precursors into the 42, 65 and 68 kDa proteolytic forms.
These results further implicate furin in the processing of
LEKTI precursors into the three C-terminal proteolytic forms
identified in HK extracts.
Figure 3. LEKTI glycosylation pattern. HK were differentiated for 24 h in high-
calcium medium and cultured for an additional 6 h in the presence of BFA at
10 mg/ml (lanes 1 and 2). COS-1 cells were transiently transfected for 48 h with
the pEF-DEST51-LEKTI construct containing LEKTI full-length cDNA (lanes
4 and 5), or with the empty pEF-DEST51 vector as control (lane 3). Twenty
micrograms of total cell extracts from HK and COS-1 cells were incubated
for 1 h at 37C in the presence (þ) or absence () of PNGase F. Samples were
resolved by SDS–PAGE (5%) and analysed by western blot using LEKTI
polyclonal a-C antibodies. Arrows indicate the positions of the 115 and
135 kDa de-glycosylated protein forms. Molecular weight markers are indicated
on the left in kDa. The results shown are representative of three to five indepen-
dent experiments.
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LEKTI expression is impaired in HK from NS patients
We investigated LEKTI expression in HK from three NS
patients, termed NS1, NS2 and NS3, whose SPINK5 mutations
introduce premature termination codons of translation [(12);
patients 10, 11 and 12, respectively].
We first compared the relative expression levels of SPINK5
transcript in normal (N) and NS patient (NS1-3) differentiated
HK by northern blot analysis. A dramatic reduction of the
3.7 kb signal was observed for all three patients compared to
control (Fig. 5A), suggesting nonsense-mediated mRNA decay
and predicting severe impairment of LEKTI expression.
LEKTI protein levels were subsequently examined by western
blot analysis of cell extracts from normal (N) and NS (NS1-3)
differentiated HK treated in the presence (Fig. 5B) or absence
(Fig. 5C) of BFA. Importantly, the full-length protein was only
detected in normal controls incubated with BFA, and not in NS
patient cell extracts (Fig. 5B). Similarly, the 42, 65 and
68 kDa proteolytic fragments were not observed in NS samples,
but were present in the control (Fig. 5C). These data confirm that
the 145 and 125 kDa full length proteins, and the 68, 65 and
42 kDa fragments, are encoded by SPINK5, and provide the first
conclusive evidence for defective expression of LEKTI in NS.
LEKTI expression in normal tissues
Paraffin wax-embedded sections of a variety of normal human
tissues were tested for reactivity with LEKTI antibodies by
immunohistochemistry. a-C polyclonal, and a-N monoclonal
and polyclonal antibodies showed similar labelling patterns
throughout the tissues investigated (Table 1). A strong immuno-
reactivity was detected in interfollicular epidermis of the skin
and was localized to the cytoplasm of keratinocytes of the
granular and uppermost spinous layers; the horny layer was
negative. In the granular layer, the labelling often appeared more
intense at the cell periphery and in the upper cytoplasm, forming
a cuff above the nucleus and resulting in a polarized appearance
(Fig. 6A). Antigen competition completely abolished the
labelling, confirming its specificity (Fig. 6B). Staining was also
observed in cells lining acrosyringeal ducts of hair follicles
(Fig. 7A–C), and in the duct of sebaceous glands (Fig. 7D). In
hair follicles, the labelling of the hair bulb was restricted to
matrical cells that differentiate into the inner root sheath and hair
shaft (Fig. 7A-4 andC).Above the hair bulb, the inner root sheath
layers and hair cuticle were stained, whilst the outer root sheath
was negative (Fig. 7B-3 and C). In the hair isthmus, reactivity
was limited to inner cells of the outer root sheath surrounding the
hair shaft (Fig. 7A-2). The follicular infundibulum displayed a
staining pattern similar to that observed in interfollicular
epidermis (Fig. 7A-1). In the thymus, LEKTI was abundantly
expressed in Hassall’s corpuscles, which represent the terminal
differentiation stages of the thymic medullary epithelium
(Fig. 7E). Strong expression was also detected in the gingival
mucosa, mainly localized to the upper half of the stratum
spinosum (Fig. 7F). An extended labelling was observed
throughout suprabasal layers of the vaginal mucosa (Fig. 7G)
Figure 4. Involvement of furin in LEKTI intracellular processing. (A) COS-1 cells were transiently transfected for 48 h with the pEF-DEST51-LEKTI construct
containing LEKTI full-length cDNA. Twenty micrograms of total cell extracts were treated for the indicated times in the presence (þ) or absence () of human
recombinant furin (2 units), at 30C. Samples were resolved by SDS–PAGE (7.5%) and analysed by western blot using LEKTI polyclonal a-C antibodies. The
asterisk indicates a 70 kDa protein band, detected in all samples incubated at 30C (lanes 2–7) including furin untreated extract (lane 7), which most likely repre-
sents a degradation product of the 145 kDa protein. (B) HK were differentiated for 24 h in high-calcium medium, and cultured for an additional 6 h in the absence
(lane 1) or presence of the indicated concentrations of furin inhibitor I (lanes 2 and 3) or BFA (10 mg/ml; lane 4). Twenty micrograms of total cell extracts were
separated and analysed as above. The asterisk indicates an unrelated protein cross-reacting with a-C antibodies. Anti-tubulin detection shows equal loading. Arrows
indicate the positions of the 42, 65, 68, 125 and 145 kDa protein bands. Molecular weight markers are indicated on the left in kDa. The results shown are repre-
sentative of three to five independent experiments.
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and uterine ectocervix (Fig. 7H). The tonsillar epithelium
(Fig. 7I) and the oesophagus (data not shown) also showed
positive staining. In contrast, no labelling was found in the
epithelia of the gastrointestinal tract, liver, lung and kidney (data
not shown). No specific staining was detected in the remainder of
the organs tested (Table 1). In all tissues examined, no labelling
was observed using the corresponding pre-immune sera (data not
shown). Further confirmation of antibody specificity was
provided by antigen competition (data not shown).
LEKTI expression in congenital erythrodermas,
keratinizing and inflammatory skin diseases
Skin sections from patients affected with congenital erythro-
dermas, inherited disorders of keratinization and inflammatory
skin diseases were tested for reactivity with LEKTI antibodies
(Table 2). Immunostaining of skin sections from 21 patients
with proven NS showed no detectable protein expression in 20
patients, including NS1, NS2 and NS3 (Fig. 8A), and very
weak and discontinuous staining in the residual granular layer
of the remaining (data not shown). In contrast, LEKTI was
detected in the epidermis of sections from all other congenital
erythrodermas, keratinizing and inflammatory skin diseases
tested. All 18 samples of neonatal and infantile erythrodermas
due to immune deficiency, atopic dermatitis or psoriasis, clearly
showed expression of LEKTI. However the staining pattern
was irregular, with areas of reduced staining alternating with
areas of normal or increased reactivity in the upper spinous
layers (Fig. 8B, C and E). In all genetic keratinizing disorders
in children or adults tested, LEKTI expression pattern was
abnormally extended to a variable number of cell layers of the
stratum spinosum. This was particularly marked in specimens
from bullous (Fig. 8D) and non-bullous (data not shown)
congenital ichthyosiform erythrodermas, lamellar (Fig. 8F) and
X-linked (data not shown) ichthyoses, and Darier’s (Fig. 8H)
and Hailey-Hailey (data not shown) diseases. In ichthyosis
vulgaris, LEKTI was expressed in the reduced granular layer
and in the uppermost cell layer of the stratum spinosum
(Fig. 8G).
Among inflammatory skin disorders, psoriasis was chosen
both in view of the well-characterized alterations in the
expression pattern of several epidermal differentiation markers
and as a possible cause of neonatal erythroderma, which can
be misdiagnosed as NS. LEKTI expression was detected in all
12 samples of chronic plaque psoriasis examined (Fig. 8I).
However, an irregular expression pattern was observed, with
areas of markedly reduced staining alternating with areas of
normal labelling intensity and extended reactivity pattern.
Decreased labelling was mainly detected in thinned suprapa-
pillary epidermis showing a highly diminished granular layer,
marked parakeratosis with neutrophil microabscesses and
leukocyte infiltration. In interpapillary epidermis of elongated
ridges, LEKTI immunodetection often appeared of normal
intensity but extended to several spinous layers. Lastly, we
analysed samples from five adult patients affected with atopic
dermatitis, all of which also proved positive for LEKTI
expression with decreased staining in spongiotic areas (data
not shown).
DISCUSSION
In this study, we report the first cellular and tissue detection of
lympho-epithelial Kazal-type related inhibitor (LEKTI) using
anti-C and anti-N terminal specific antibodies. We demonstrate
that LEKTI is a marker of epithelial differentiation whose
expression, like most differentiation-specific proteins (23,24),
is regulated in cultured keratinocytes by external calcium
concentrations. We have shown that LEKTI is expressed in
differentiated HK as two N-glycosylated precursor proteins of
Table 1. Reactivity of LEKTI antibodies on normal human tissues
Positive Negative
Stratified epithelia Simple epithelia Others
Skin (10/10) Lung (0/10) Heart (0/4)
Thymus (11/11) Liver (0/6) Central nervous system (0/2)
Gingiva (4/4) Kidney (0/12) Cerebellum (0/1)
Tonsil (2/2) Stomach (0/7) Peripheral nerves (0/3)
Oesophagus (4/4) Duodenum (0/5) Ovary (0/2)
Vagina (4/4) Colon (0/11) Testis (0/4)
Uterine ectocervix (4/4) Appendix (0/2) Uterus (0/5)
Rectum (0/1) Prostate (0/4)
Seminal vesicle (0/2)
Breast (0/5)
Adrenal gland (0/4)
Pancreas (0/3)
Thyroid (0/8)
Salivary gland (0/4)
Bone marrow (0/4)
Lymph node (0/5)
Spleen (0/9)
Sections of various tissues were analysed by immunohistochemistry, as described in Materials and Methods. For each tissue, the number of positive samples out of
the total tested is indicated in parentheses.
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145 and 125 kDa. However, under the experimental conditions
used, these proteins were only detected when ER to Golgi
transport was inhibited with brefeldin A, indicating rapid
intracellular processing in a post-ER compartment of the
secretory pathway. In addition, we identified three C-terminal
proteolytic fragments of 42, 65 and 68 kDa in both cell extracts
and conditioned medium. Time course analysis over 72 h of cell
differentiation showed no further processing of these proteo-
lytic forms (data not shown). These data suggest that the 42, 65
and 68 kDa polypeptides represent stable, and thereby
potentially biologically active, forms of LEKTI. They also
indicate that the inhibitory action of LEKTI-derived peptides/
polypeptides (14,15) could target secreted and/or cell-surface-
exposed serine proteases. In contrast to HK, no processing of
the overexpressed 145 kDa full-length protein was observed in
COS-1 cells, further indicating that the proteolytic forms
identified in HK do not result from auto-catalytic cleavage
events. This result also suggested that the 125 kDa protein was
not generated through auto-cleavage of the 145 kDa isoform in
the ER of HK.
We have also shown that in vitro cleavage of the over-
expressed 145 kDa precursor by furin generates proteins of 65
and 68 kDa, whose sizes match those of two C-terminal
proteolytic forms identified in HK. This finding suggests that
the 65 and 68 kDa proteins, but not those of 125 kDa and
42 kDa, originate from the cleavage of the 145 kDa precursor in
HK. Interestingly, preliminary data indicate that the 125 kDa
isoform results from alternative processing of the SPINK5 pre-
mRNA in keratinocytes (A. Tartaglia-Polcini et al., manuscript
in preparation), suggesting that the 42 kDa fragment could
originate from the cleavage of this isoform. We have also
Figure 5. Comparative analysis of SPINK5 and LEKTI expression levels in HK
from normal (N) and NS patients (1–3). HK were differentiated for 24 h in
high-calcium medium. (A) Twenty micrograms of total RNA were analysed
by northern blot, as described in Materials and Methods. Hybridization with
a 32P-labelled SPINK5-cDNA specific probe shows a 3.7 kb signal. GAPDH
detection allows the comparison between samples loading. (B and C)
Differentiated HK were cultured for an additional 6 h in the presence (B) or
absence (C) of BFA (10mg/ml). Twenty micrograms of total cell extracts were
separated by SDS–PAGE (7.5%) and analysed by western blot using LEKTI
polyclonal a-C antibodies. Arrows indicate the positions of the 42, 65, 68,
125 and 145 kDa protein bands. RNA size (A) and molecular weight (B and
C) markers are indicated on the left in kb and kDa, respectively. The results
shown are representative of three to five independent experiments.
Figure 6. LEKTI expression in normal human skin. Immunohistochemical
staining of paraffin embedded sections with LEKTI polyclonal a-N antibodies
was performed as described in Materials and Methods. LEKTI is strongly
expressed in the cytoplasm of keratinocytes of the epidermal granular and
uppermost spinous layers; the polarized appearance of the labelling in the gran-
ular layer, resulting from a more intense reactivity in the upper cytoplasm, is
evident (A). Preincubation of a-N antibodies with the recombinant antigen
GST-D1-D6 prior to immunodetection results in a complete absence of reactiv-
ity, confirming the specificity of labelling (B). Bars: 25mm (A); 50mm (B).
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shown that treatment of HK with the furin inhibitor, Dec-
RVKR-CMK, prevents the processing of both endogenous
precursors, further implicating furin in the intracellular
processing of LEKTI. This is likely to occur in the trans-
Golgi network where the active form of furin resides (25). Co-
localization of furin and LEKTI in the granular layer of the
epidermis (22) further supports this hypothesis. However,
expression of other subtilisin-like proprotein convertases
(SPC), including PACE4, PC5/PC6, PC7/8 and PC8, have
been demonstrated in human epidermis (22,26), raising the
possibility that these endo-proteases could also be involved in
the proteolytic processing of LEKTI.
The number of consensus sequences for SPC cleavage
identified within LEKTI could generate at least 14 polypeptides
(13). However, identification of the 42, 65 and 68 kDa C-
terminally processed forms in this study, together with a 30 kDa
polypeptide (16), reveals that only a selected proportion of
these sites are used during the in vivo processing of LEKTI.
Interestingly, processing of the N-terminal half of LEKTI
seems to generate single domains (D1, D5, D6) (14,15), whilst
the C-terminal half produces larger multi-domain fragments.
These fragments may result from selective post-translational
proteolysis (27) with a different processing in various tissues
depending on the enzymes involved. The reasons we could not
detect D1, D5 and D6 in HK using a-N antibodies raised
against D1–D6 remain unclear; however, this could be due to
the lack of epitope recognition within these domains and/or the
rapid degradation of single protein domains under the
experimental conditions used.
LEKTI tissue distribution pattern clearly demonstrates a
specific expression in the most differentiated viable layers
of stratified epithelial tissues (Table 1). These included
Figure 7. Human tissue distribution of LEKTI. Immunohistochemical staining of paraffin sections from normal human tissues (Table 1) with LEKTI polyclonal a-
N antibodies was performed as described in Materials and Methods. In the hair follicle (A–C), a strong labelling is evident in the matrical cells of the anagen bulb
(A-4 and C), in all internal root sheath layers (cuticle, Huxley’s and Henle’s layers), in the hair shaft cuticle in the lower portion of the follicle (A-3, B and C), in the
innermost layers of the outer root sheath at the level of the isthmus (A-2) and in the infundibulum (A-1). Intense LEKTI expression is also observed in the duct of
sebaceous glands (D), in thymic Hassall’s corpuscles (E), suprabasal epithelial layers of the gingival (F), vaginal (G) and uterine ectocervix (H) mucosa, as well as
in the tonsillar epithelium (I). ORS, outer root sheath; IRS, inner root sheath; HS, hair shaft; C, cuticle; He, Henle’s layer; Hu, Huxley’s layer; MC, matrical cells.
Bars: 25 mm (E); 50mm (D, F–I); 100mm (B, C); 165mm (A).
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keratinizing (skin and its appendages, gingiva and thymus), as
well as non-keratinizing (tonsil, oesophagus, vagina and uterine
ectocervix) epithelia. In the epidermis, LEKTI expression was
mainly restricted to the granular layer, where critical biochem-
ical and morphological changes of terminal differentiation lead
to cornification (28). In hair follicle, the strong expression of
LEKTI in matrical cells of the bulb, the hair shaft cuticle and
inner root sheath, suggest a possible role in hair growth and
differentiation. In non-keratinizing epithelia, LEKTI expression
was more diffuse throughout the upper half of the spinous
layers, supporting a role for the protein in earlier stages of
epithelial differentiation.
We have shown that the absence of LEKTI expression in HK
and epidermis is a common feature of NS. Although very low
levels of LEKTI could be detected in skin sections of one patient,
these results demonstrate that loss of LEKTI expression is the
major molecular mechanism underlying NS. In contrast, normal
or slightly reduced levels of LEKTI were detected in all other
inherited and acquired skin diseases examined, including a
number of clinically resembling skin disorders (Table 2). This
finding reveals that defective expression of LEKTI in the
epidermis is a diagnostic feature of NS, thus providing the basis
for the powerful use of LEKTI antibodies for rapid, early and
reliable diagnosis of NS. In a variety of other inherited
keratinizing disorders tested, LEKTI expression appears to be
upregulated and is extended to several spinous layers. The various
epidermal responsesmounted to compensate for altered epidermal
permeability barrier in these diseases, from cytokine production
by keratinocytes to the modulation of epidermal calcium gradient
(23,29,30), could be involved in driving increased expression
of LEKTI. Interestingly, LEKTI expression pattern in these
diseases does not match that of any known epithelial differentia-
tion protein, such as loricrin, involucrin or filaggrin (31,32).
This indicates that specific mechanisms are involved in the
transcriptional/post-transcriptional regulation of LEKTI expres-
sion. In psoriasis and neonatal/infantile erythrodermas (due to
immune deficiency or atopy), an irregular LEKTI staining pattern
is detected. In particular, decreased expression corresponds to the
presence of an intense lympho-mononuclear inflammatory
infiltrate invading the epidermis, suggesting that some inflamma-
tory cytokines could downregulate LEKTI expression.
Although the biological function(s) of LEKTI is still
unknown, its specific expression in highly differentiated
regions of lympho-epithelial tissues, together with the clinical
features of NS patients, predicts key roles in a number of
physiological processes. It is likely that LEKTI plays a role in
terminal epidermal differentiation and/or corneocyte desqua-
mation (13), as suggested by its restricted expression in the
granular layer of the epidermis, and impaired keratinization and
cornification in NS. Among possible targets are the stratum
corneum trypsin- and chymotrypsin-like enzymes (SCTE and
SCCE, respectively) (33), whose defective inhibition by LEKTI
would result in over desquamation of corneocytes (13). Other
putative targets are trypsin-like serine proteases, including the
membrane-type serine protease 1 (MT-SP1) (34), which could
mediate inhibition of keratinocyte differentiation through
activation of PAR-2 (protease-activated receptor-2) at the
keratinocyte surface (35). The extent of atopic manifestations
in NS, which are not seen in other congenital ichthyoses, also
predicts a role for LEKTI as a downregulator of inflammatory
and/or immune allergic responses (36). Two recent independent
studies reporting association between SPINK5 missense
variants and atopic dermatitis (37,38) further support this
assumption. Among the serine proteases secreted during the
inflammation process, the trypsin-like mast cell tryptase is a
major mediator of numerous allergic and inflammatory
conditions (39). Induction of inflammatory cytokines cell
secretion (40), mast cell activation (41), and eosinophil and
neutrophil recruitment (42) by the mast cell tryptase, via PAR-2
activation (43), indicates that this serine protease may mediate
an amplification mechanism of the inflammatory response.
Lack of downregulation by LEKTI could thus trigger a cycle of
chronic allergen-induced inflammation in NS, and potentially,
in common atopic diseases. Finally, many allergens themselves
are serine proteases (44), including the major house dust-mite
and pollen (45). It is thus possible that lack of inhibition of
some of these activities by LEKTI may also contribute to the
allergen hyper-responsiveness associated with NS pathology.
Despite absence of significant immune function abnormalities
in NS patients (6), the strong and localized expression of
LEKTI in thymic Hassall’s corpuscles suggests that the protein
could be involved in the regulation of T cell maturation.
Although the functional significance of Hassall’s corpuscles
remains to be determined, recent findings suggest that these are
involved both in maturation of developing thymocytes (46),
and activation and tolerization of mature T cells (47). For its
specific expression in Hassall’s corpuscles (48), the trypsin-like
kallikrein 6 (KLK6) serine protease represents a potential target
of LEKTI inhibitory activity. LEKTI expression in differen-
tiated and keratinizing areas of the hair follicle (Fig. 7A–C) and
sebaceous glands (Fig. 7D) suggests a possible role in growth
and differentiation of pilosebaceous units. This assumption is
further supported by the specific hair shaft abnormality,
trichorrhexis invaginata (TI), and slow growing hair feature
Table 2. Congenital erythrodermas and other keratinizing disorders examined in
this study for LEKTI expression by immunohistochemical analysis of skin
sections
Disease Cases examined
Netherton syndrome 21
Other neonatal/infantile erythrodermas 18
SCID 5
Omenn syndrome 3
Atopic dermatitis 5
Psoriasis 5
Keratinizing disorders in children or adults 51
Ichthyosis vulgaris 3
Lamellar ichthyosisa 9
Non-bullous congenital ichthyosiform erythrodermaa 5
Bullous congenital ichthyosiform erythroderma 2
X-linked ichthyosis 2
Other rare ichthyosesb 3
Darier’s disease 5
Hailey-Hailey disease 5
Atopic dermatitis 5
Psoriasis 12
aTwo cases due to TGM1 mutations.
bIchthyosis of Siemens (1), ichthyosis hystrix (1) and Sjo¨gren–Larsson
syndrome (1).
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observed in NS patients. Interestingly, LEKTI co-localizes with
SCCE and SCTE in hair (inner root sheath and innermost
layers of the outer root sheath in the uppermost follicle) and
sebaceous (duct) follicles (33,49). This observation raises the
possibility that, like in epidermis, LEKTI may regulate the
activity of these serine proteases in pilosebaceous follicles.
Lack of LEKTI expression in NS hair may lead to impaired
keratinization of structures of the hair shaft, which could
account for softening and collapse of its distal part into its
proximal portion when driven upward by the growing force,
resulting in the formation of TI bamboo nodes (50). Reports of
morphological abnormalities in the keratogenous zone of the
hair cortex, and unkeratinized hair cuticle cells in TI (50), also
correlate with the predicted lack of LEKTI expression in this
location. The predisposition of NS patients to cutaneous
infections of bacterial and viral origins could be attributed to
the severe skin permeability barrier dysfunction, facilitating
invasion by microorganisms. However, their persistent/recur-
rent character, unique to NS among ichthyoses (6), suggests
additional loss of an important host-defense mechanism in the
skin. Anti-microbial and anti-viral activities have been
described for a number of serine protease inhibitors (51),
including the antileukoprotease (ALP) (52), and b defensins
secreted by keratinocytes (53). It is thus possible that LEKTI-
derived bioactive peptides/polypeptides share similar activities
as part of the innate immune response in the skin. Given its
tissue distribution, a role for LEKTI in the general anti-
microbial protection of mucous epithelia is also anticipated.
Surprisingly, particular organs relevant to NS pathology such as
lung, kidney and digestive tract were negative for LEKTI
Figure 8. Expression of LEKTI in Netherton syndrome compared to inherited and acquired skin diseases (Table 2). Immunohistochemical staining of skin sections
from patients affected with Netherton syndrome (A) and other skin diseases (B–I) were performed with LEKTI polyclonal a-N antibodies, as described in Materials
and Methods: severe combined immunodeficiency syndrome (SCID) (B); Omenn syndrome (C); bullous congenital ichthyosiform erythroderma (D); erythroderma
due to atopic dermatitis (E); lamellar ichthyosis (F); ichthyosis vulgaris (G); Darier’s disease (H); and psoriasis (I). Note the intense staining of an increased number
of spinous cell layers in bullous congenital ichthyosiform erythroderma (D), lamellar ichthyosis (F), and Darier’s disease (H). In SCID (B), Omenn syndrome (C),
atopic dermatitis (E) and psoriasis (I), areas of reduced staining are evident and often match the thinned parakeratotic suprapapillary epidermis where exocytosis of
the inflammatory infiltrate is more prominent, while areas of staining extension to suprabasal cell layers are observed. In ichthyosis vulgarilis (G), LEKTI detection
was similar to that obtained in normal skin. Bars: 50mm (A, B, E–H); 100mm (C, D, I).
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expression in normal individuals (Table 1). This suggests that
life-threatening complications associated with NS, such as
bronchopneumonia, malnutrition and metabolic disorders (6),
are not primarily due to defective LEKTI function(s) in these
organs, and may reflect a secondary effect resulting from
failure to produce LEKTI in other tissues.
LEKTI full-length recombinant protein has recently been shown
to inhibit the enzymatic activities of plasmin, trypsin, subtilisin A,
cathepsin G and elastase (54). This result supports the involve-
ment of LEKTI in multiple biological pathways relevant to tissue
homeostasis, inflammation and anti-microbial defense.
Interestingly, the native D6 peptide shows a selective and more
potent trypsin inhibition than the full-length recombinant protein,
suggesting that the inhibitory potency of processed LEKTI
domains against specific proteinases could be significantly higher
than that of the precursor(s). These findings, together with our
present data, further suggest that LEKTI proteolytic polypeptides
represent bioactive forms, with different target specificities. The
identification of the novel processed forms of LEKTI described in
this study provides the basis for future functional and structural
analysis of fragments with physiological relevance.
MATERIALS AND METHODS
Materials
All reagents, chemicals and antibodies were purchased from
Sigma (Poole, UK) unless otherwise stated. Cell culture media
were obtained from Invitrogen (Paisley, UK).
Tissue samples
Awide variety of normal human tissues, listed in Table 1, were
retrieved from the archives of the Department of Pathology of
Purpan Hospital in Toulouse (France). Skin specimens from
21 patients affected with Netherton syndrome (NS) and other
genetic and acquired disorders of keratinization, listed in
Table 2, were obtained from the archives of the Service of
Histopathology of the IDI-IRCCS in Rome (Italy), the
Department of Pathology in Toulouse, and the Department of
Dermatology of Necker Hospital in Paris (France). Tissue
samples had been obtained for diagnostic or research purposes.
The Central Oxfordshire Research Ethic Committee approved
the study and all patients gave informed consent.
Cloning of LEKTI full-length cDNA into
pEF-DEST51 expression vector
LEKTI full-length cDNA (GenBank AJ228139) was generated
by long-range PCR (Expand Long Template PCR System;
Roche Molecular Biochemicals, E. Sussex, UK) using total
cDNA from differentiated HK (obtained as described below) as
a template. The PCR product was subcloned into pCRII-TOPO
vector (TOPO TA Cloning Kit; Invitrogen) and transferred into
the mammalian expression vector pEF-DEST51 using the
Gateway technology, according to the manufacturer’s instruc-
tions (Invitrogen). pEF-DEST51-LEKTI construct was fully
sequenced using the Big Dye Terminator Sequencing Kit and an
ABI377 automated sequencer (Applied Biosystem, Cheshire,
UK).
Cell culture and transfections
Normal and NS human primary keratinocytes (HK) were
isolated from skin biopsies as previously described (55). HK
were expanded on a feeder layer of lethally irradiated 3T3-J2
mouse fibroblasts in keratinocyte-growth medium, following
the method described by Rheinwald and Green (56,57). For all
experiments, HK were grown in the absence of 3T3 feeder
layers in low calcium (<0.1mM) keratinocyte serum-free
medium (K-SFM) supplemented with epidermal growth factor
(0.4 ng/ml) and bovine pituitary extract (25 mg/ml). Cells were
seeded in low calcium K-SFM at a density corresponding to
80% confluence in 60 15mm tissue culture dishes or eight-
well chamber slides (Nalge Nunc International, Naperville, IL,
USA) for northern/western blot and immunofluorescence
microscopy analysis, respectively. Cell differentiation was
induced for 24 h in high calcium (1.2mM) K-SFM. Further
treatments with brefeldin A (BFA) and furin inhibitor I
(Dec-RVKR-CMK; Calbiochem, Nottingham, UK) were per-
formed for 6 h at 10 mg/ml and 25–50 mM respectively, in high
calcium K-SFM.
COS-1 cells were grown in Dulbecco’s modified Eagle
medium supplemented with 10% fetal calf serum, 100U/l
penicillin/streptomycin and 10 ng/ml L-glutamine. Cells were
plated in 60 15mm tissue culture dishes at 70% confluence
and transiently transfected with pEF-DEST51 or pEF-DEST51-
LEKTI vectors (2.5 mg DNA), using FuGENETM 6 Transfection
Reagent according to the manufacturer’s recommendations
(Roche Molecular Biochemicals). Transfected cells were
maintained in culture for 48 h before proceeding to western blot
analysis.
RNA extraction, reverse transcriptase–PCR and
northern blotting
Total RNAwas isolated from normal and NS differentiated HK
using Trizol (Invitrogen) according to the manufacturer’s
instructions. cDNA was generated from normal HK total RNA
by reverse-transcription using the AMV reverse transcriptase
(Roche Diagnostic Spa, Monza, Italy) and random hexamers. It
was subsequently used as a template for the PCR amplification
of a 273 bp cDNA product comprised within the 30 untranslated
region of LEKTI cDNA sequence. PCR conditions were as
described below with an annealing temperature of 59C, and
primers used were as follows: 50-CAGGAAGATTGTTGAAAG
CCA-30 (sense, nucleotides 3239–3259) and 50-ATTGAACA
GGCAGTTGGACAG-30 (antisense, nucleotides 3491–3511).
The PCR product was radiolabelled and used as a probe for the
northern blot analysis of 20 mg of total RNA extracts, following
standard methods (58). To assess uniformity of RNA loading
and transfer, the membrane was further hybridized with a
radiolabelled probe corresponding to the ubiquitously expressed
gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH;
GenBank NM002046). Quantification of the hybridization
signals was performed by densitometric scanning using a
GS-750 densitometer (Bio-Rad, Hercules, CA, USA).
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Polyclonal LEKTI antibodies production
Rabbit polyclonal antibodies were raised against the recombi-
nant N-terminal (D1–D6) and C-terminal (D13–D15) parts of
LEKTI, and were termed a-N and a-C antibodies, respectively.
Construction of pGEX4T1-D1–D6 and pGEX3X-D13–D15
bacterial expression vectors. Fragments of LEKTI cDNA
encoding the protein domains D1–D6 (nucleotides 52–1278)
and D13–D15 (nucleotides 2483–3241) were generated by
PCR using the following primers: D1 sense, 50-CCGCTCGA
GCAAGATGCTGCCAGTAAGAATGAA-30; D6 antisense,
50-CCGCTCGAGTTGTCTTTTGTTTCTTGATTCGCC-30;
D13 sense, 50-GCGGGATCCTGGAAAGGGAAGCAGCTG-30,
and D15 antisense, 50-CGGAATTCTGTCATTCGTCAGAC
GGG-30. PCR cycling conditions were: 94C for 10min, 35
cycles comprising 94C for 30 s, 66C (D1–D6) or 55C
(D13–D15) for 45 s, and 72C for 1min, followed by a final
extension at 72C for 10min. PCR products were fully
sequenced as decribed above, and subcloned into the
Glutathione-S-Transferase (GST) gene fusion vectors
pGEX-4T-1 and pGEX-3X (Amersham Pharmacia Biotech,
Amersham, UK) using XhoI and EcoRI/BamHI restriction sites
for D1–D6 and D13–D15, respectively. pGEX-D1–D6
and pGEX-D13–D15 constructs were transformed into BL21
and TOPO10 E. coli strains (Stratagene, Amsterdam,
Netherlands), respectively.
Expression and purification of recombinant GST-fusion
proteins. Procedures were essentially performed as previously
described (59). Briefly, cell cultures were grown at 37C in
Luria Broth base (Invitrogen) medium containing 100 mg/ml
ampicillin to an OD600nm of 0.8. Protein expression was then
induced by addition of IPTG to 0.1mM, and cultures were
grown overnight at room temperature. Cells were harvested,
and lysed by sonication. Sonicates were clarified from insoluble
material by centrifugation at 16 000g, 4C for 30min. GST-
D1–D6 (74.6 kDa) and GST-D13–D15 (55.6 kDa) were affinity
purified using glutathione sepharose 4B beads, according to the
manufacturer’s recommendations (Amersham Pharmacia
Biotech).
Immunizations. Immunizations of rabbits with the recombi-
nant antigens GST-D1–D6 and GST-D13–D15 were performed
by Eurogentec Bel S.A (Herstal, Belgium) and Primm (Milan,
Italy), respectively.
Serum purification. a-C and a-N crude antisera were purified
by affinity chromatography for the respective antigens, using
NHS-activated Sepharose1 4 Fast Flow (Amersham
Pharmacia Biotech) and the AminoLink Plus Immobilization
Trial purification procedure (Pierce, Rockford, IL, USA),
respectively, following manufacturers’ instructions.
Monoclonal LEKTI antibody production
BALB/c mice were immunized four times with 50 mg of
recombinant GST-D1–D6 at 2 week intervals, once subcuta-
neously and three times intraperitoneally, in association with
complete (first injection), incomplete (second and third
injections) and without (fourth injection) Freund’s adjuvant
(Calbiochem, La Jolla, CA, USA). Three days after the fourth
immunization, fusion of the spleen cells with the non-Ig-
producing myeloma cell line X63 Ag8 653 was performed
using standard techniques (60). When hybridoma growth could
be detected, supernatants were tested for antibody-binding
activity using an enzyme linked immunosorbent assay
(ELISA). Of the 295 clones generated, one was found to
secrete anti-D1–D6 antibody, as determined by ELISA and
immunohistochemistry (see below). The selected hybridoma
was cloned by limiting dilution. Isotope characterization
showed that the anti-D1–D6 monoclonal antibody belongs to
an IgG1 subclass.
Immunofluorescence microscopy
Cells were fixed in ice-cold methanol for 30min and processed
for immunofluorescence analysis, as previously described (61).
The primary antibodies used were LEKTI polyclonal a-N
(11 mg/ml) and a-C (4 mg/ml) antibodies, the corresponding
rabbit pre-immune sera used at the same dilutions, and the
monoclonal anti-calreticulin antibody (Calbiochem).
Secondary antibodies were goat anti-rabbit conjugated to
FITC and sheep anti-mouse conjugated to TRITC. For
competition experiments, a-N and a-C antibodies were pre-
incubated for 1 h at room temperature with 2.5-fold excess
(weight) of the respective recombinant antigens GST-D1–D6
and GST-D13–D15, prior to immunodetection. Cells were
mounted in Vectorshield in the presence or absence of
propidium iodide (Vector Laboratories, Peterborough, UK),
and examined under a Nikon Optiphot with a 60 oil
objective. Images were captured using an MRC 1024
confocal laser microscope and collected using Lasersharp
software (Bio-Rad).
Western blotting
Cells were lysed in a suitable volume of ice-cold lysis buffer
(50mM Tris–HCl pH 8.0, 150mM NaCl, 5mM EDTA, 1% NP-
40, 1mM PMSF and 1 mg/ml each of antipaine, chymostatin,
leupeptin and pepstatin). Lysates were incubated for 30min on
ice and clarified from the insoluble materiel by centrifugation at
16 000g, 4C for 3min. Conditioned media were concentrated
by overnight precipitation at 20C in the presence, per ml of
medium, of 3.6ml of ethanol and 100 ml of the solution mix
20mM N-ethylmalaeimide, 10mM EDTA, 1mM PMSF,
100mM 2-mercaptoethanol–acetic acid in 0.1 M Tris–HCl
buffer pH 7.4. Proteins were recovered by centrifugation at
13 000g, 4C for 30min and resuspended in a suitable volume
of ice-cold lysis buffer. Protein samples were quantified using
the BCA protein assay kit (Pierce, Rockford, IL, USA), and
20 mg were fractionated by SDS–polyacrylamide gel electro-
phoresis (PAGE). Proteins were transferred onto Immobilon-P
membranes (Millipore, Herts, UK) using the Hoefer Semiphor
semi-dry transfer unit (Amersham Pharmacia Biotech). Blots
were immunostained following standard protocols (60). First
antibodies were LEKTI polyclonal a-N (1.9 mg/ml), a-C
(1.2 mg/ml), and monoclonal a-N (1 mg/ml) antibodies, and
the corresponding rabbit pre-immune sera used at the same
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dilutions. Secondary antibodies were donkey anti-rabbit or
sheep anti-mouse antibodies conjugated to horseradish perox-
idase (Amersham Pharmacia Biotech). Proteins were visualized
using the ECL detection system according to the manufac-
turer’s instructions (Amersham Pharmacia Biotech).
Competition experiments were performed as described above
using 2.5-fold excess (weight) of the recombinant antigens. To
verify equal sample loading, membranes were stripped
following Amersham’s ECL detection system instructions,
and reprobed using the anti-tubulin monoclonal antibody.
PNGase F (New England Biolabs, Hitchin, UK) and human
recombinant furin sample treatments were performed for 1 h at
37 and 30C, respectively, according to the manufacturer’s
instructions.
Immunohistochemistry
LEKTI a-N polyclonal and monoclonal antibodies worked on
paraffin sections only, whilst a-C polyclonal antibodies also
worked on frozen sections. These antibodies were used on a
large panel of normal human tissue samples (Table 1), as well
as on skin biopsies from patients affected with NS or other skin
disorders (Table 2). Tissue samples were fixed in 10% neutral
buffered formalin. Four-micrometer sections were prepared
from paraffin-wax-embedded tissues and their reactivity with
LEKTI antibodies was investigated by immunohistochemistry.
Prior to immunodetection, specimens were deparaffinized,
rehydrated and processed as described elsewhere (62).
Antigen retrieval of dewaxed sections was performed by heat-
treatment for 40min using a water bath at 95C in 10mM
citrate buffer pH 6.0 supplemented with 1% Tween 20, or using
the Target Retrieval Solution (Dako, Trappes, France). Sections
were immunostained for 30min at room temperature with
polyclonal a-N (11 mg/ml) or a-C (4 mg/ml) antibodies diluted
in PBS containing 0.3% BSA, or with the undiluted a-N
monoclonal antibody (5 mg/ml). Tissue sections were incubated
with the streptavidin-biotin-peroxidase complex (ABC method)
using the StrepABComplex/HRP Duet (mouse/rabbit) kit
(Dako). Extensive washing with PBS containing 0.3% BSA
was performed between each step. Labelling was revealed
using diaminobenzidine tetrahydrochloride and hydrogen
peroxide, and nuclei were counterstained with hematoxylin.
Negative controls were included for each sample by omitting
the primary antibody. The labelling specificity was verified
using the corresponding pre-immune sera at the same
concentrations and by competition experiments, as described
above, using 10-fold excess (weight) of the recombinant
antigens.
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